Home › Compare › KNRLF vs ABBV
KNRLF yields 3703.70% · ABBV yields 3.06%● Live data
📍 KNRLF pulled ahead of the other in Year 1
Combined, KNRLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KNRLF + ABBV for your $10,000?
Kontrol Technologies Corp., through its subsidiaries, provides energy management, emission compliance, and air quality solutions and services in Canada and the United States. It offers turn-key solutions to building owners and asset managers in the commercial, industrial, and multi-residential sector, which include software to analyze the management of heating, cooling, and ventilation (HVAC) systems; design and engineering of improvements and/or retrofits; and ongoing mission critical services. The company also provides integrated installations of heating, ventilation, cooling, and business automation systems to its customers; greenhouse gas verification, installation of critical emission management systems, and stack testing for environmental emissions; and Kontrol BioCloud, a solution to provide real-time viral detection technology. In addition, it offers energy auditing, monitoring and verification, energy project assessment, mechanical, electrical, and renewable design, as well as LEED facilitation services; monitoring, operation, and service of essential heating, cooling, ventilation, and utility systems; stack emission testing, continuous emission testing, power generation, due diligence, odour assessment and analytics, compliance, and other engineering services; and monitoring solutions, services, and product sales. The company is headquartered in Vaughan, Canada.
Full KNRLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.